The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model

Annals of Nuclear Medicine

Volumn 13, Issue 5, 1999, Pages 303-308

  Chung, June Key ^a,b   Chang, Young Soo ^a   Lee, Yong Jin ^a   Kim, Young Ju ^a   Jeong, Jae Min ^a   Lee, Dong Soo ^a   Jang, Ja June ^a   Lee, Myung Chul ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Autoradiography; F 18 ; F 18 FDG; Fluoroerythronitroimidazole; Sarcoma; Tumor size

Indexed keywords

AMMONIUM FLUORIDE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; NITROIMIDAZOLE; TETRABUTYLAMMONIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOMA; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0345103356     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164868     Document Type: Article

References (24)

1. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 27: 94-106, 1997.
2. Hawkins RA, Hoh C, Glaspy J, et al. The role of positron emission tomography in oncology and other whole-body application. Semin Nucl Med 22: 268-284, 1992.
3. Biskupiak JE, Krohn KA. Second generation hypoxia imaging agents. J Nucl Med 34: 411-413, 1993.
4. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194: 795-800, 1995.
5. Keyes Jr JW. SUV: standard uptake value or silly useless value? J Nucl Med 36: 1836-1839, 1995.
6. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intramural distribution of tridated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 36: 1854-1861, 1995.
7. Patel KR, Tin GW, Williams LE, et al. Biodistribution of phospholipid vesicles in mice bearing Lewis lung carcinoma and granulation. J Nucl Med 26: 1048-1055, 1985.
8. Ogihara I, Kojima S, Jay M. Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 27: 1300-1307, 1986.
9. Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: Effect on monoclonal antibody uptake in tumor models. J Nucl Med 27: 422-427, 1986.
10. Yoshida K, Rivoire ML, Divgi CR, Niedzwiechi D, Cohen AM, Sigurdson ER. Effect of tumor size on monoclonal antibody uptake in a metastatic model. J Surg Oncol 49: 249-252, 1992.
11. 18F]fluorotrimethylsilane. Int Appl Radiat Isot 36: 375-378, 1985.
12. Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J Natl Cancer Inst 13: 1299-1377, 1953.
13. Epenetos AA, Nimmon CC, Arklie J. Detection of human cancer in an animal model using radiolabeled tumor-associated monoclonal antibodies. Br J Cancer 46: 1-8, 1982.
14. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of Fluorine-18 fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980, 1992.
15. Gullino PM, Grantham FH. Studies on the exchange of fluids between host and tumor. II. The blood flow of hepatomas and other tumors in rats and mice. J Natl Cancer Inst 27: 1465-1470, 1961.
16. Peterson H-J, ed. Tumor blood flow compared with normal tissue blood flow in tumor blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumors. Boca Raton FL, CRC Press Inc., pp. 103-114, 1979.
17. Stanley JA, Shipley WU, Steel GG. Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. Br J Cancer 36: 105-113, 1977.
18. Shimamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 77: 908-915, 1986.
19. DiChiro G, DeLa Paz RL, Brooks RA, et al. Glucose utitlization of cerebral gliomas: measurements by [F-18]fluorodeoxyglucose and positron emission tomography. Neurology 32: 623-648, 1982.
20. Tyler JL, Diksic M, Villemure J-G, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28: 1123-1133, 1987.
21. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 32: 1485-1490, 1991.
22. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 34: 12-17, 1993.
23. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325-329, 1992.
24. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiation Oncology Biol Phys 27: 455-464, 1993.